Full-size Left-side Hidden
REFERENCES

1.  PAAT (Program Against African Trypanosomiasis). Information System. 2006.Online. Available: http://wwwfaoorg/paat/html/gishtm

2. Rogers DJ, Williams BG: Monitoring trypanosomiasis in space and time. Parasitology  1993; 106(suppl):S77-S92.

3. Jordan AM: Trypanosomiasis Control and African Rural Development,  London, Longman, 1986.

4. WHO : Control and surveillance of African trypanosomiasis,  Geneva, World Health Organization, 1998.

5. Abel PM, Kiala G, Loa V, et al: Retaking sleeping sickness control in Angola. Trop Med Int Health  2004; 9(1):141-148.

6. Lutumba P: Trypanosomiasis control, democratic republic of Congo, 1993-2003. Emerg Infect Dis  2005; 11(9):1382-1389.

7. Robays J, Bilengue MM, Stuyft PV, et al: The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo. Trop Med Int Health  2004; 9(5):542-550.

8. Ruiz JA, Simarro PP, Josenando T: Control of human African trypanosomiasis in the Quicama focus, Angola. Bull World Health Organ  2002; 80(9):738-745.

9. Simarro PP, Franco JR, Ndongo P, et al: The elimination of Trypanosoma brucei gambiense sleeping sickness in the focus of Luba, Bioko Island, Equatorial Guinea. Trop Med Int Health  2006; 11(5):636-646.

10. Balasegaram M, Harris S, Checchi F, et al: Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo. Bull WHO  2006; 84:777-782.

11. Anonymous : Weekly Epidemiological Record  2006; 8:71-80.

12. Hoare CA: The Trypanosomes of Mammals (A Zoological Monograph),  Oxford, Blackwell Scientific, 1972.

13. Vickerman K: Antigenic variation in trypanosomes. Nature  1978; 273(5664):613-617.

14. Buscher P, Bin Shamamba SK, Ngoyi DM, et al: Susceptibility of Grammomys surdaster thicket rats to Trypanosoma brucei gambiense infection. Trop Med Int Health  2005; 10(9):850-855.

15. Inoue N, Narumi D, Mbati PA, et al: Susceptibility of severe combined immuno-deficient (SCID) mice to Trypanosoma brucei gambiense and T. b. rhodesiense. Trop Med Int Health  1998; 3(5):408-412.

16. Truc P, Aerts D, McNamara JJ, et al: Direct isolation in vitro of Trypanosoma brucei from man and other animals, and its potential value for the diagnosis of Gambian trypanosomiasis. Trans R Soc Trop Med Hyg  1992; 86(6):627-629.

17. Dukes P, Kaukas A, Hudson KM, et al: A new method for isolating Trypanosoma brucei gambiense from sleeping sickness patients. Trans R Soc Trop Med Hyg  1989; 83(5):636-639.

18. Maina NW, Kunz C, Brun R: Cryopreservation of Trypanosoma brucei gambiense in a commercial cryomedium developed for bull semen. Acta Trop  2006; 98(3):207-211.

19. Maina NWN, Oberle M, Otieno C, et al: Isolation and propagation of Trypanosoma brucei gambiense from sleeping sickness patients in South Sudan. Trans R Soc Trop Med Hyg  2007; 101(6):540-546.

20. Tomlinson S, Raper J: Natural human immunity to trypanosomes. Parasitol Today  1998; 14(9):354-359.

21. Pays E, Vanhollebeke B, Vanhamme L, et al: The trypanolytic factor of human serum. Nat Rev Microbiol  2006; 4(6):477-486.

22. Rickman LR, Robson J: The blood incubation infectivity test: A simple test which may serve to distinguish Trypanosoma brucei from T. rhodesienses. Bull WHO  1970; 42(4):650-651.

23. Jenni L, Brun R: A new in vitro test for human serum resistance of Trypanosoma (T.) brucei. Acta Trop  1982; 39(3):281-284.

24. Radwanska M, Chamekh M, Vanhamme L, et al: The serum resistance-associated gene as a diagnostic tool for the detection of Trypanosoma brucei rhodesiense. Am J Trop Med Hyg  2002; 67(6):684-690.

25. Berberof M, Perez-Morga D, Pays E: A receptor-like flagellar pocket glycoprotein specific to Trypanosoma brucei gambiense. Mol Biochem Parasitol  2001; 113(1):127-138.

26. Jenni L, Marti S, Schweizer J, et al: Hybrid formation between African trypanosomes during cyclical transmission. Nature  1986; 322(6075):173-175.

27. Gibson WC, Mizen VH: Heritability of the trait for human infectivity in genetic crosses of Trypanosoma brucei ssp. Trans R Soc Trop Med Hyg  1997; 91(2):236-237.

28. Simo G, Herder S, Njiokou F, et al: Trypanosoma brucei s.l.: characterisation of stocks from Central Africa by PCR analysis of mobile genetic elements. Exp Parasitol  2005; 110(4):353-362.

29. Balmer O, Palma C, MacLeod A, et al: Characterization of di-, tri- and tetranucleotide microsatellite markers with perfect repeats for Trypanosoma brucei and related species. Molecular Ecology Notes  2006; 6:508-510.

30. Tibayrenc M, Kjellberg F, Ayala FJ: A clonal theory of parasitic protozoa: the population structures of Entamoeba, Giardia, Leishmania, Naegleria, Plasmodium, Trichomonas, and Trypanosoma and their medical and taxonomical consequences. Proc Natl Acad Sci USA  1990; 87(7):2414-2418.

31. Gibson W, Miles MA: Application of new technologies to epidemiology. Brit Med Bull  1985; 41(2):115-121.

32. Godfrey DG, Baker RD, Rickman LR, et al: The distribution, relationships and identification of enzymic variants within the subgenus Trypanozoon. Adv Parasitol  1990; 29:1-39.

33. Stevens JR, Godfrey DG: Numerical taxonomy of Trypanozoon based on polymorphisms in a reduced range of enzymes. Parasitology  1992; 104:75-86.

34. Stevens JR, Lanham SM, Allingham R, et al: A simplified method for identifying subspecies and strain groups in Trypanozoon by isoenzymes. Ann Trop Med Parasitol  1992; 86(1):9-28.

35. Herder S, Simo G, Nkinin S, et al: Identification of trypanosomes in wild animals from southern Cameroon using the polymerase chain reaction (PCR). Parasite  2002; 9(4):345-349.

36. Buyst H: The epidemiology of sleeping sickness in the historical Luangwa valley. Ann Soc Belge Med Trop  1977; 57(4-5):349-359.

37. MacLean L, Chisi JE, Odiit M, et al: Severity of human African trypanosomiasis in East Africa is associated with geographic location, parasite genotype, and host inflammatory cytokine response profile. Infect Immun  2004; 72(12):7040-7044.

38. Geigy R, Mwambu PM, Kauffmann M: Sleeping sickness survey in Musoma district, Tanzania. IV. Examination of wild mammals as a potential reservoir for T. rhodesiense. Acta Trop  1971; 28(3):211-220.

39. De Greef C, Imberechts H, Matthyssens G, et al: A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense. Mol Biochem Parasitol  1989; 36(2):169-176.

40. Xong HV, Vanhamme L, Chamekh M, et al: A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell  1998; 95(6):839-846.

41. Cibulskis RE: Genetic variation in Trypanosoma brucei and the epidemiology of sleeping sickness in the Lambwe Valley, Kenya. Parasitology  1992; 104(Part 1):99-109.

42. Gibson WC, Wellde BT: Characterization of Trypanozoon stocks from the South Nyanza sleeping sickness focus in Western Kenya. Trans R Soc Trop Med Hyg  1985; 79(5):671-676.

43. Onyango RJ, van Hoeve K, de Raadt P: The epidemiology of T. rhodesiense sleeping sickness in Alego location, central Nyanza, Kenya. I. Evidence that cattle may act as reservoir hosts of trypanosomes infective to man. Trans R Soc Trop Med Hyg  1966; 60:175.

44. Gibson WC, Gashumba JK: Isoenzyme characterization of some Trypanozoon stocks from a recent trypanosomiasis epidemic in Uganda. Trans R Soc Trop Med Hyg  1983; 77(1):114-118.

45. Baldry DAT, Chaudhuri MFB: Epidemiology of African trypanosomiasis. Insect Sci Appl  1980; 1(1):85-93.

46. Welburn SC, Maudlin I: Tsetse-trypanosome interactions: rites of passage. Parasitol Today  1999; 15(10):399-403.

47. Chappuis F, Loutan L, Simarro P, et al: Options for field diagnosis of human African trypanosomiasis. Clin Microbiol Rev  2005; 18(1):133-146.

48. Magnus E, Vervoort T, Van Meirvenne N: A card agglutination test with stained trypanosomes (CATT) for the serological diagnosis of T.b. gambiense trypanosomiasis. Ann Soc Belge Med Trop  1978; 58:169-176.

49. Chappuis F, Stivalello E, Adams K, et al: Card agglutination test for trypanosomiasis (CATT) end-dilution titer and cerebrospinal fluid cell count as predictors of human African trypanosomiasis (Trypanosoma brucei gambiense) among serologically suspected individuals in Southern Sudan. Am J Trop Med Hyg  2004; 71:313-317.

50. Inojosa WO, Augusto I, Bisoffi Z, et al: Diagnosing human African trypanosomiasis in Angola using a card agglutination test: observational study of active and passive case finding strategies. BMJ  2006; 332(7556):1479.

51. Simarro PP, Ruiz JA, Franco JR, et al: Attitude towards CATT-positive individuals without parasitological confirmation in the African Trypanosomiasis (T.b. gambiense) focus of Quicama (Angola). Trop Med Int Health  1999 Dec; 4(12):858-861.

52. Buscher P, Lejon V, Magnus E, et al: Improved latex agglutination test for detection of antibodies in serum and cerebrospinal fluid of Trypanosoma brucei gambiense infected patients. Acta Trop  1999; 73(1):11-20.

53. Deborggraeve S, Claes F, Laurent T, et al: Molecular dipstick test for diagnosis of sleeping sickness. J Clin Microbiol  2006; 44(8):2884-2889.

54. Woo PT: The haematocrit centrifuge for the detection of trypanosomes in blood. Can J Zool  1969; 47(5):921-923.

55. Lumsden WGR, Kimber CD, Evans DA, et al: Trypanosoma brucei: Miniature anion exchange centrifugation for detection of low parasitemias: Adaptation for field use. Trans R Soc Trop Med Hyg  1979; 73:313-317.

56. Doua F, Miezan TW, Sanon Singaro JR, et al: The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. Am J Trop Med Hyg  1996; 55(6):586-588.

57. Lejon V, Legros D, Savignoni A, et al: Neuro-inflammatory risk factors for treatment failure in ‘early second stage’ sleeping sickness patients treated with Pentamidine. J Neuroimmunol  2003; 144(1-2):132-138.

58. Lejon V, Buscher P: Cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up [Review Article]. Trop Med Int Health  2005; 10(5):395-403.

59. Lejon V, Buscher P, Sema NH, et al: Human African trypanosomiasis: A latex agglutination field test for quantifying IgM in cerebrospinal fluid. Bull WHO  1998; 76(6):553-558.

60. Lejon V, Legros D, Richer M, et al: IgM quantification in the cerebrospinal fluid of sleeping sickness patients by a latex card agglutination test. Trop Med Int Health  2002; 7(8):685-692.

61. Buguet A, Bisser S, Josenando T, et al: Sleep structure: a new diagnostic tool for stage determination in sleeping sickness. Acta Trop  2005; 93(1):107-117.

62. Blum J, Schmid C, Burri C: Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop  2006; 97(1):55-64.

63. Schultzberg M, Ambatsis M, Samuelsson EB, et al: Spread of Trypanosoma brucei to the nervous system: early attack on circumventricular organs and sensory ganglia. J Neurosci Res  1988; 21(1):56-61.

64. Pepin J: African trypanosomiasis.   In: Strickland GT, ed. Hunter's Tropical Medicine and Emerging Infectious Diseases,  8th edn.. Philadelphia: Saunders; 2000:643-654.

65. Manson-Bahr PEC, Bell DR: African Trypanosomiasis. Manson's Tropical Diseases,  19th edn.. London: Baillière and Tindall; 1987:54-73.

66. Molyneux DH, Pentreath V, Doua F: African trypanosomiasis in man.   In: Cook GC, ed. Manson's Tropical Diseases,  20th edn.. London: Saunders; 1996:1171-1196.

67. Kristensson K, Bentivoglio M: Pathology of African trypanosomiasis.   In: Dumas M, Bouteille B, Buguet A, ed. Progress in Human African Trypanosomiasis, Sleeping Sickness,  Paris: Springer; 1999:157-182.

68. Mansfield JM, Paulnock DM: Regulation of innate and acquired immunity in African trypanosomiasis. Parasite Immunol  2005; 27(10-11):361-371.

69. MacLean L, Odiit M, Sternberg JM: Nitric oxide and cytokine synthesis in human African trypanosomiasis. J Infect Dis  2001; 184(8):1086-1090.

70. Baetselier PD, Namangala B, Noel W, et al: Alternative versus classical macrophage activation during experimental African trypanosomosis. Int J Parasitol  2001; 31(5-6):575-587.

71. Lejon V, Reiber H, Legros D, et al: Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J Infect Dis  2003; 187(9):1475-1483.

72. Sternberg J: Human African trypanosomiasis: clinical presentation and immune response. Parasite Immunol  2004; 26(11-12):469-476.

73. Bisser S, Ouwe-Missi-Oukem-Boyer ON, Toure FS, et al: Harbouring in the brain: A focus on immune evasion mechanisms and their deleterious effects in malaria and human African trypanosomiasis. Int J Parasitol  2006; 36(5):529-540.

74. Vincendeau P, Bouteille B: Immunology and immunopathology of African trypanosomiasis. An Acad Bras Cienc  2006; 78(4):645-665.

75. Berriman M, Ghedin E, Hertz-Fowler C, et al: The genome of the African trypanosome Trypanosoma brucei. Science  2005; 309(5733):416-422.

76. El-Sayed NM, Myler PJ, Blandin G, et al: Comparative genomics of trypanosomatid parasitic protozoa. Science  2005; 309(5733):404-409.

77. Hutchinson OC, Webb H, Picozzi K, et al: Candidate protein selection for diagnostic markers of African trypanosomiasis. Trends Parasitol  2004; 20(11):519-523.

78. Agranoff D, Stich A, Abel P, et al: Proteomic fingerprinting for the diagnosis of human African trypanosomiasis. Trends Parasitol  2005; 21(4):154-157.

79. Apted FIC: Treatment of human trypanosomiasis.   In: Mulligan HW, ed. The African Trypanosomiasis,  London: Allen & Unwin; 1970:684-710.

80. Sands M, Kron MA, Brown RB: Pentamidine: A review. Review in Infectious Diseases  1985; 7:625-634.

81. Doua F, Yapo FB: Human trypanosomiasis in the Ivory Coast - therapy and problems. Acta Trop  1993; 54(3-4):163-168.

82. Bronner U, Doua F, Ericsson O, et al: Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'Ivoire. Trans R Soc Trop Med Hyg  1991; 85(5):608-611.

83. Berger BJ, Lombardy RJ, Marbury GD, et al: Metabolic N-hydroxylation of pentamidine in vitro. Antimicrob Agents Chemother  1990; 34(9):1678-1684.

84. Wang CC: Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol  1995; 35:93-127.

85. Collins JM, Klecker RWJ, Yarchoan R, et al: Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol  1986; 26:22-26.

86. Chijioke CP, Umeh RE, Mbah AU, et al: Clinical pharmacokinetics of suramin in patients with onchocerciasis. Eur J Clin Pharmacol  1998; 54(3):249-251.

87. Fairlamb AH, Bowman BR: Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect in respiration and growth rate in vivo. J Biochem Pathol  1980; 1:315-333.

88. Friedheim EAH: Mel B in the treatment of human trypanosomiasis. Am J Trop Med Hyg  1949; 29:173-180.

89. Brun R, Schumacher R, Schmid C, et al: The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Int Health  2001; 6(11):906-914.

90. Burri C, Nkunku S, Merolle A, et al: Efficacy of new, concise treatment schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet  2000; 355:1419-1425.

91. Schmid C, Richer M, Bilenge CM, et al: Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: Confirmation from a multinational study (Impamel II). J Infect Dis  2005; 191(11):1922-1931.

92. Jannin J, Cattand P: Treatment and control of human African trypanosomiasis. Curr Opin Infect Dis  2004; 17(6):565-571.

93. Blum J, Nkunku S, Burri C: Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health  2001; 6(5):390-400.

94. Soignet SL, Tong WP, Hirschfeld S, et al: Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol  1999; 44(5):417-421.

95. Keiser J, Ericsson O, Burri C: Investigations of the metabolites of the trypanocidal drug melarsoprol. Clin Pharmacol Therapeutics  2000; 67(5):478-488.

96. Pepin J, Milord F, Mpia B, et al: An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Trans R Soc Trop Med Hyg  1989; 83(4):514-517.

97. Van Nieuwenhove S: Present strategies in the treatment of human African trypanosomiasis.   In: Dumas M, Bouteille B, Buguet A, ed. Progress in Human African Trypanosomiasis, Sleeping Sickness,  Paris: Springer; 1999:253-280.

98. Burri C, Baltz T, Giroud C, et al: Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy  1993; 39(4):225-234.

99. Chappuis F, Udayraj N, Stietenroth K, et al: Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis  2005; 41(5):748-751.

100. Burri C, Brun R: Eflornithine for treatment of human African trypanosomiasis. Parasitol Res  2003; 90(suppl 1):S49-S52.

101. Dow MM: Ornidyl label. Ornidyl Patient Information  1991.

102. Bacchi CJ, Nathan HC, Hutner SH, et al: Polyamine metabolism: a potential therapeutic target in trypanosomes. Science  1980; 210(4467):332-334.

103. Pegg AE, McCann PP: Polyamine metabolism and function. Am J Physiol  1982; 243(5):C212-C221.

104. Gonnert R: Nifurtimox: causal treatment of Chagas' disease. Drug Res  1972; 22(9):1563.

105. Priotto G, Fogg C, Balasegaram M, et al: Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: A randomized clinical trial in Uganda. PLoS Clin Trials  2006; 1(8):e39.1-8.

106. Wegner DH, Rohwedder RW: Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Drug Res  1972; 22(9):1635-1641.

107. Paulos C, Paredes J, Vasquez I, et al: Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. Int J Clin Pharmacol Ther Toxicol  1989; 27(9):454-457.

108. Docampo R, Moreno SN: Free radical metabolism of antiparasitic agents. Fed Proc  1986; 45(10):2471-2476.

109. Legros D, Evans S, Maiso F, et al: Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg  1999; 93:439-442.

110. Stanghellini A, Josenando T: The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health  2001; 6(5):330-334.

111. Pepin J, Mpia B: Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001. Emerg Infect Dis  2005; 11(6):921-927.

112. Burri C, Keiser J: Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health  2001; 6(5):412-420.

113. Matovu E, Enyaru JC, Legros D, et al: Melarsoprol refractory T.b. gambiense from Omugo, north-western Uganda. Trop Med Int Health  2001; 6(5):407-411.

114. Matovu E, Geiser F, Schneider V, et al: Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Mol Biochem Parasitol  2001; 117(1):73-81.

115.  Bisser S, Van Nieuwenhove S, Lejon V, et al. New therapeutic regimen for sleeping sickness. Description, results and lessons from the clinical trial established in Bwamanda (Equateur, RDC). Bruges: COST B9 Meeting; 2000.

116. Immtech : Immtech Report Fiscal Year End 2008 Results.  Online. Available: http://www.immtechpharma.com/documents/news_061808a.pdf

117.  Anonymous. $22.6 Million Gates Foundation Grant Targets New Treatment for African Sleeping Sickness. 2006. Online. Available: http://wwwuncedu/news/archives/may06/may06shtml

118. Bouchet B, Legros D, Lee E: Key indicators for the monitoring and evaluation of control programmes of human African trypanosomiasis due to Trypanosoma brucei gambiense. Trop Med Int Health  1998; 3(6):474-481.